Brain Metastases from Non-Small Cell Lung Cancer with EGFR or ALK Mutations: A Systematic Review and Meta-Analysis of Multidisciplinary Approaches

Raj Singh 1, Eric J. Lehrer 2, Stephen Ko 3, Jennifer Peterson 4, Yanyan Lou 5, Alyx Porter 6, Rupesh Kotecha 7, Paul D. Brown 5, 8, Daniel M. Trifiletti 9

1. Department of Radiation Oncology, Virginia Commonwealth University, Richmond, USA 2. Department of Radiation Oncology, Ichan School of Medicine at Mount Sinai, New York, USA 3. Radiation Oncology, Mayo Clinic, Rochester, USA 4. Department of Radiation Oncology, Mayo, Jacksonville, USA 5. Medical Oncology, Mayo Clinic, Rochester, USA 6. Neurology, Mayo Clinic, Rochester, USA 7. Radiation Oncology, Miami Cancer Institute, Miami, USA 8. Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA 9. Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, USA

Corresponding author: Raj Singh, rsingh1492@gmail.com

Categories: Radiation Oncology
Keywords: non-small cell lung cancer, brain metastases, tyrosine kinase inhibitors

How to cite this abstract

Abstract

Objectives: To analyze outcomes of non-small cell lung cancer (NSCLC) patients with brain metastases harboring EGFR or ALK mutations and examine for differences between tyrosine kinase inhibitors (TKIs) alone, radiotherapy (RT) alone (either whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)), or combined TKIs and RT.

Methods: Thirty studies were identified. Patients: with brain metastases from NSCLC. Intervention: initial TKIs alone with optional salvage RT, RT alone, or TKIs and RT. Control: wild-type NSCLC and TKIs alone for mutational and treatment analysis, respectively. Outcomes: overall survival (OS) and intracranial progression-free survival (PFS). Setting: studies with mutation information.

Results: A total of 2,649 patients were included. Patients with ALK and EGFR mutations had significantly higher median OS (48.5 months, p<0.0001; and 20.9 months; p=0.0006, respectively) compared to wild-type patients (9.9 months). Similar median OS was noted between TKIs and RT (28.3 months), RT alone (32.2 months; p=0.22), or TKIs alone (23.9 months; p=0.2). Patients treated with TKIs and RT had higher median PFS (18.6 months; p=0.06) compared to TKIs alone (13.6 months) with no difference between TKIs and RT vs. RT alone (16.9 months; p=0.72). No PFS difference was found between WBRT and TKI (25.2 months; p=0.72) vs. WBRT alone (24 months) or SRS and TKI (16.7 months; p=0.56) vs. SRS alone (13.6 months).

Conclusions: NSCLC patients with brain metastases harboring EGFR or ALK mutations have superior OS compared to wild-type patients. No PFS or OS benefit was found with the addition of TKIs to RT.